- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Ken Cohen Speaks on the Impact of Market Power on Biosimilar Uptake
Ken Cohen, MD, director of translational research for Optum Care, speaks on the future of more biosimilars hitting the market, and how they will influence value-based care.
Ken Cohen, MD, director of translational research for Optum Care, speaks on the future of more biosimilars hitting the market, and how they will influence value-based care.
Transcript
As more and more biosimilars are hitting the market, how is the approach to biosimilars changing? And how will the approach of prescribing a biologic versus a biosimilar change?
Being able to differentiate between biosimilars won't be possible, because large [randomized controlled trials] for each of those biosimilars have not been done in head-to-head comparative fashion. There is recognition that the clinical efficacy of those is equivalent and, therefore, it will come back to market powers in terms of cost and availability.
There will be gaming of the system where the branded agents will try to leverage formulary placement with access to their other drugs and other things that pharma has done over the years to try to protect branded agents. I think in a value-based world, you make the best decision based on the individual cost effectiveness of a single product. Over time, I think that will create the landscape where biosimilars can gain footing and ultimately decrease cost of care for patients.
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
